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The Multi-Ethnic Study of Atherosclerosis was initiated in July 2000 to investigate the prevalence, correlates, and
progression of subclinical cardiovascular disease (CVD) in a population-based sample of 6,500 men and women
aged 45–84 years. The cohort will be selected from six US field centers. Approximately 38% of the cohort will be
White, 28% African-American, 23% Hispanic, and 11% Asian (of Chinese descent). Baseline measurements will
include measurement of coronary calcium using computed tomography; measurement of ventricular mass and
function using cardiac magnetic resonance imaging; measurement of flow-mediated brachial artery endothelial
vasodilation, carotid intimal-medial wall thickness, and distensibility of the carotid arteries using ultrasonography;
measurement of peripheral vascular disease using ankle and brachial blood pressures; electrocardiography; and
assessments of microalbuminuria, standard CVD risk factors, sociodemographic factors, life habits, and
psychosocial factors. Blood samples will be assayed for putative biochemical risk factors and stored for use in
nested case-control studies. DNA will be extracted and lymphocytes will be immortalized for genetic studies.
Measurement of selected subclinical disease indicators and risk factors will be repeated for the study of progression
over 7 years. Participants will be followed through 2008 for identification and characterization of CVD events,
including acute myocardial infarction and other coronary heart disease, stroke, peripheral vascular disease, and
congestive heart failure; therapeutic interventions for CVD; and mortality.
cardiovascular diseases; cardiovascular system; cohort studies; coronary disease; epidemiologic methods; 
prospective studies
Abbreviations: CVD, cardiovascular disease; MESA, Multi-Ethnic Study of Atherosclerosis.
Prospective epidemiologic studies of cardiovascular
disease (CVD) have traditionally relied on the occurrence of
clinically overt events, such as myocardial infarction, stroke,
and coronary heart disease death, to identify factors
predicting development of disease. This design has served
well to identify many CVD risk factors, but more recent
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study designs utilizing earlier, subclinical endpoints hold
promise for furthering our capacity to predict and prevent
CVD. The Multi-Ethnic Study of Atherosclerosis (MESA)
was initiated by the National Heart, Lung, and Blood Insti-
tute to further understanding of the pathogenesis of athero-
sclerosis and other CVD by 1) providing accurate,
quantifiable measures of early CVD; 2) characterizing CVD
before it has become clinically manifest and therefore
subject to interventions that disrupt its natural history; and
3) optimizing study of the progression of subclinical disease.
The study will include populations that will provide informa-
tion about specific ethnic groups and allow comparisons
among groups at different levels of risk that may provide
clues to pathogenesis. This paper describes the rationale and
design of MESA.
There are several advantages to using measures of subclin-
ical disease—that is, disease detected noninvasively before it
produces clinical signs and symptoms—in studies of disease
etiology. First, although clinical events are the usual targets
of clinical and public health intervention, studies based
solely on clinical events may lead to distortion of risk rela-
tions due to underdetection and biased ascertainment of
disease. Second, subclinical disease measures can enhance
studies of CVD risk and prevention by allowing examination
of its early stages. Third, because subclinical disease is
asymptomatic and previously unknown to participants, it is
unlikely to have any direct impact on health behaviors, such
as lifestyle modification or medication use, that may alter
relations of risk with disease. (This applies particularly to
cross-sectional analyses; it is expected that knowledge of
baseline subclinical disease imparted to study participants
often results in interventions that will modify the risk of clin-
ical outcomes longitudinally.) Finally, the continuous nature
of most subclinical measures greatly increases power to
detect risk associations compared with discrete measures,
that is, the presence or absence of clinical disease.
MESA will build upon the successful experience of
several CVD epidemiologic studies begun since the 1980s
that have included objective measures of subclinical CVD.
Examples of these measures are echocardiographically
measured left ventricular mass and carotid ultrasonographic
measurement of arterial wall thickness, which have been
used in the Framingham Study (1), the Cardiovascular
Health Study (2), and the Atherosclerosis Risk in Communi-
ties Study (3) to detect underlying subclinical disease and
predict clinical CVD (4). Recent developments in the
measurement of cardiovascular structure and function make
imaging of other aspects of subclinical disease and
measuring functional aspects of the vasculature in popula-
tion-based studies feasible and accurate, providing specific,
detailed information that relates more directly to pathology.
Coronary calcium is a specific marker of atherosclerosis (5)
that has been included in the Coronary Artery Risk Develop-
ment in Young Adults Study (6) and in subgroups in the
Atherosclerosis Risk in Communities Study and the Cardio-
vascular Health Study (7). When quantified by computed
tomography, coronary calcium has correlations of 0.90 or
greater with histologic coronary plaque area (8, 9), and it can
be used to identify persons at increased risk for coronary
heart disease events (10, 11), although some studies of the
predictive value of coronary calcium have been criticized for
drawing participants from clinical or high-risk populations.
Cardiac magnetic resonance imaging, which has not been
utilized in previous epidemiologic studies, is capable of
providing precise measures of left ventricular mass, diastolic
and systolic function, and aortic distensibility (12–14).
Magnetic resonance imaging of the carotid wall may provide
an opportunity for improved assessment of plaque character-
istics (15) and their relation to clinically overt disease in the
carotid arterial bed (16). Vascular stiffness, other aspects of
arterial mechanics, and endothelial function are additional
noninvasive measures of “early” functional changes in the
vasculature that are related to existing disease, risk factor
exposure, and risk factor alteration (17–20). Some measures
of arterial structure and dynamics may be obtained relatively
quickly, inexpensively, and noninvasively and thus could
have clinical application as screening and monitoring tools
or as a means of guiding therapy (21–24). MESA will
include all of these measures, with cardiac magnetic reso-
nance imaging providing measures previously obtained by
echocardiography and, in a subset, carotid magnetic reso-
nance imaging. The predictive value of these measures will
be compared and combined to obtain a thorough evaluation
of cardiovascular physiology and pathology.
Findings from studies of risk factors for subclinical CVD
have implications for prevention beyond that of clinical
CVD (25–27). The risk of clinical events associated with
subclinical disease measures has been shown to be graded
and continuous (1, 2, 4, 11), similar to risk associated with
conventional CVD risk factors such as blood pressure and
serum cholesterol, suggesting that interventions yielding
even modest reductions in levels of subclinical disease may
have a significant impact on reducing CVD risk throughout
the general population. For such interventions to be
designed, factors contributing to the development and
progression of subclinical disease must be identified.
Despite the value of understanding subclinical disease in
asymptomatic populations, it is clear that there is a qualita-
tive difference between subclinical and clinical disease
burden that precludes replacement of the former with the
latter. The use of subclinical disease measures is controver-
sial for use in clinical trials as a surrogate outcome measure
(28). In MESA, however, subclinical disease is an outcome
measure in itself, and it is being used as a window into the
early pathogenesis of clinical disease.
Atherosclerosis is a complex process involving inflamma-
tion and cellular proliferation in the arterial wall that is medi-
ated by a variety of growth factors, cytokines, thrombotic
factors, and vasoactive molecules (29). Mature lesions
exhibit calcification (30), which is mediated by cells similar
to osteoblasts (31, 32). Infectious agents may be involved in
the initiation and/or progression of atherosclerotic lesions
(33). Roles have been suggested for a host of other factors in
the etiology of atherosclerosis and of clinical events (34),
including hemostatic factors (35, 36), factors related to lipo-
protein metabolism, insulin resistance (37), homocysteine
(29), immune factors (38), inflammation markers (39),
specific fatty acids (40, 41), indicators of oxidative stress,
and circulating markers of endothelial function such as
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Prospective investigation of these potential risk factors
should suggest pathophysiologic mechanisms likely to be
involved. MESA will systematically evaluate each of these
domains in the whole cohort or in informative subgroups.
Advances in techniques for identifying genetic markers
and sequencing genes and in statistical methods for
analyzing genetic epidemiologic data have opened opportu-
nities for estimating gene frequencies in populations,
exploring the relations between genes and phenotypes, and
understanding gene-gene and gene-environment interactions
(43). Characterization of subclinical disease in MESA
should result in more precise and valid phenotypic character-
ization of CVD than in past studies, enhancing the ability to
relate specific blood markers and specific genes or chromo-
somal regions to phenotypes.
The incidence and prevalence of CVD differ among some
racial and ethnic groups in the United States. Information on
subclinical CVD in some groups is sparse, however. MESA
will include a substantial proportion of previously under-
studied minority groups whose prevalence of risk factors and
CVD risk attributable to specific risk factors have been
shown or hypothesized to differ from that of the majority of
the population. African Americans tend to have higher CVD
rates than do Whites, particularly among women (44, 45).
Hispanic populations in the United States, notwithstanding
their ethnic and cultural heterogeneity, tend to have lower
rates of CVD and general mortality than the general popula-
tion does, despite high risk factor levels, although data are
not consistent in this regard (46–48). Pacific Asians (partic-
ularly Chinese Americans, Japanese Americans, and immi-
grants from Southeast Asia) have lower morbidity and
mortality rates than do Whites (49, 50). However, there are
few data available on this group, particularly Pacific-Asian
women in the United States. By including several ethnic
groups, MESA will provide information on the progression
of subclinical CVD in these groups, including whether risk
factor-outcome relations differ across groups. In recognition
of the need to obtain more health information on ethnic
minority groups, in recent years policies governing funding
of clinical research by the National Institutes of Health have
mandated the inclusion of minorities (51). MESA will
contribute importantly to accumulating data on CVD and its
risk factors in minority groups.
MATERIALS AND METHODS
Study objectives
The objectives of MESA are 1) to determine characteris-
tics related to progression of subclinical CVD to clinical
CVD; 2) to determine characteristics related to progression
of subclinical CVD itself; 3) to assess ethnic, age, and sex
differences in subclinical disease prevalence, risk of progres-
sion, and rates of clinical CVD; 4) to determine relations of
newly identified factors with subclinical disease and to
determine their incremental predictive value over estab-
lished risk factors; and 5) to develop methods, suitable for
application in future screening and intervention studies, for
characterizing risk among asymptomatic persons.
Study design
Study participants will include 6,500 men and women, in
equal numbers, who are aged 45–84 years and free of clinical
CVD at baseline, including four racial/ethnic groups from
six US communities. Approximately 38 percent of the cohort
will be White, 28 percent will be African-American, 23
percent will be Hispanic, and 11 percent will be Asian,
predominantly of Chinese descent. The first examination,
which began in July 2000 and will be conducted over a 24-
month period, is designed to be the most comprehensive.
The second (from July 2002 to January 2004) and third (from
January 2004 to July 2005) examinations, conducted over 18
months each, will include repetitions of selected baseline
measurements and new measures that could not be included
at baseline. The fourth examination (from July 2005 to July
2007), to be conducted over a 24-month period, will include
repetition of selected measures to be studied for temporal
trends. The MESA protocol, including information about the
source populations from which recruitment occurred,
detailed exclusion criteria, contact information for the inves-
tigators, and other information, is available on the World
Wide Web at www.mesa-nhlbi.org.
Subclinical CVD prevalence and progression and CVD
events.   With coronary artery calcium as an indicator, the
prevalence of subclinical disease is expected to range from
approximately one fourth in the youngest women to virtually
100 percent in the oldest participants (52). Dramatic differ-
ences in the prevalence of coronary calcium with age and the
findings of longitudinal studies (53, 54) suggest that progres-
sion is easily observable and measurable.
With the baseline cross-sectional data, for an alpha error of
5 percent, the study will have more than 95 percent power to
identify relations between risk factors with a prevalence of at
least 10 percent in the cohort and the presence of coronary
calcium, with an odds ratio of 1.5 or greater (table 1, top).
The power to test similar hypotheses in women and
Hispanics will be 81 percent and 59 percent, respectively.
Analytical methods that utilize the continuous nature of
coronary calcium will significantly enhance power.
It is expected that there will be approximately 330 coro-
nary heart disease events, defined as coronary heart disease
death or nonfatal myocardial infarction, over the first 6 years
of follow-up (table 2). The rates shown in table 2 are based
on observed events in the Atherosclerosis Risk in Communi-
ties Study and the Cardiovascular Health Study for Whites
and Blacks (unpublished data), with the assumption that
event rates in Hispanic subgroups would be 80 percent of
those in the White subgroup (46) and that event rates in the
Asian subgroup would be 60 percent of those in the White
subgroup (55). To take into account possible interventions
that could result from participants’ and their physicians’
discovering subclinical CVD, we decreased the estimated
event rate in one fifth of the cohort (those with the highest
coronary calcium scores) by one third. With these assump-
tions, the power to detect a relative risk of 2.0 associated
with the presence of a risk factor in 10 percent of the popula-
tion would be more than 95 percent in the entire cohort, 70
percent in women, and less than 50 percent in Hispanics
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power to test these hypotheses in different subgroups is
available in the Web-based protocol at www.mesa-nhlbi.org.
Study communities.   The MESA cohort is being drawn
from six regions in the United States: Baltimore City and
Baltimore County, Maryland; Chicago, Illinois; Forsyth
County, North Carolina; Los Angeles County, California;
New York, New York; and St. Paul, Minnesota. At each site,
approximately 1,083 eligible participants will be recruited,
with equal numbers of men and women, according to speci-
fied age/race/ethnicity proportions. Information about the
source populations from which the cohort is being recruited
may be found in the Web-based protocol.
Recruitment.   Each of the six field centers will recruit an
equal number of men and women from two or more of the
racial/ethnic groups. The expected marginal distributions of
race/ethnicity, overall and at each field center, are shown in
table 3. In designing center-specific recruitment goals, it was
deemed important to have overlapping ethnic groups among
field centers to minimize confounding of ethnicity by site.
Except when random digit dialing is used, an informa-
tional brochure is being mailed to households in targeted
areas. Within 14 days, households are contacted by tele-
phone; the language spoken in the home is determined; and a
questionnaire is administered in English, Spanish,
Cantonese, or Mandarin to introduce the study and collect
eligibility information. All eligible persons are enumerated.
To augment recruitment of elderly members of minority
groups, toward the end of the recruitment period, partici-
pants were asked to refer elderly persons to the study. A
complete list of the exclusion criteria is available in the Web-
based protocol. Other than exclusions made because of a
lack of age or race/ethnicity eligibility, exclusions will be
made to eliminate prevalent CVD or for reasons of safety or
TABLE 1.   Statistical power to test hypotheses related to coronary artery 
calcium level in the Multi-Ethnic Study of Atherosclerosis*
* Power estimates are based on an EGRET sample size program, logistic
regression for a cohort study design, adjustment for age and sex (estimates for
women are adjusted for age only), analytical estimation methods (84), and an
alpha level of 0.05.
† MESA, Multi-Ethnic Study of Atherosclerosis.
Cross-sectional analyses: prevalence of a cardiovascular disease risk factor related to the 
prevalence of coronary calcification in the MESA† cohort and in subgroups of women and 
Hispanics
Prevalence (%)





Entire cohort (n = 
6,500) (prevalence 
of coronary calcium 
at baseline = 40%)
Women (n = 3,250) 
(prevalence of 
coronary calcium 
at baseline = 20%)
Hispanics (n = 
1,495) (prevalence 
of coronary calcium 
at baseline = 40%)
10 1.5 >95 81 59
2.0 >95 >95 >95
30 1.5 >95 >95 91
2.0 >95 >95 >95
Development of clinical events: prediction of events from a cardiovascular disease risk factor 
over a period of 5 years
Prevalence of 
risk factor (%) Relative risk
Statistical power (%)
Entire cohort Women Hispanics
10 1.5 63 <50 <50
2.0 >95 70 <50
30 1.5 91 ∼50 <50
2.0 >95 92 72
TABLE 2.   Expected rates of coronary heart disease death and 
nonfatal myocardial infarction in the Multi-Ethnic Study of 
Atherosclerosis over a period of 6 years*
* Assumes that there are 6,500 participants aged 45–84 years
who were free of coronary heart disease at baseline. Other
assumptions are given in the text. Event rates are based on those
observed in the Atherosclerosis Risk in Communities Study (1987–
1994) and the Cardiovascular Health Study (1989–1997)
(unpublished data).
Event rate (%) No. of events
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feasibility. Those with prevalent CVD will be excluded to
optimize the study of subclinical CVD progression and
predictors of clinical CVD.
Examination components
Informed consent is obtained from participants upon their
arrival at the study clinic. Table 4 provides a list of the
planned components by examination. Specific variables on
which data will be obtained as measures of subclinical
disease are listed in the Appendix. The institutional review
boards of the six field centers have approved the study
protocol.
The components of the first examination are as follows.
Information is gathered on questionnaires to ascertain each
participant’s contacts, demographic data, Social Security
number (to facilitate tracking and linking with the National
Death Index), tobacco usage, passive smoke exposure,
TABLE 3.   Ethnic distribution goals for participants in the Multi-Ethnic Study of Atherosclerosis, overall and by field 
center
Whites African Americans Hispanics Asian Americans Total
No. % No. % No. % No. % No. %
Forsyth County, North 
Carolina 542 50 542 50 1,083 100
St. Paul, Minnesota 542 50 542 50 1,083 100
Chicago, Illinois 542 50 271 25 271 25 1,083 100
New York, New York 217 20 379 35 488 45 1,083 100
Baltimore, Maryland 542 50 542 50 1,083 100
Los Angeles County, 
California 108 10 108 10 433 40 433 40 1,083 100
Overall 2,492 38 1,842 28 1,463 23 704 11 6,500 100
TABLE 4.   Components of the Multi-Ethnic Study of Atherosclerosis, by examination*
* Examination components and proportions or numbers in subsets, particularly for
examinations 2, 3, and 4, are subject to change.














Medical history X X X X
Personal history, demographic data, 
and socioeconomic status X X X X
Medications X X X X
Psychosocial assessment X X X X
Diet assessment X
Physical activity X X X X
Family history X
Anthropometry X X X X
Blood pressure X X X X
Electrocardiography X X
Spot urine collection for 
microalbuminuria X
Phlebotomy X X X X
Carotid ultrasound X
Ankle brachial index X X
Endothelial function X
Arterial wave form collection X
Cardiac CT† scanning X 50% 50% 25%
Cardiac MRI† scanning X 25%
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alcohol consumption, medical conditions, access to medical
care, family history of CVD, reproductive history (in
women), and current use of prescription and nonprescription
medications and supplements (56). Physical activity is
measured by using a detailed, semiquantitative questionnaire
adapted from the Cross-Cultural Activity Participation Study
(B. Ainsworth, University of South Carolina, personal
communication, 2000). Usual diet during the previous year
is characterized by means of a food frequency questionnaire
modified from the Insulin Resistance Atherosclerosis Study
instrument, in which comparable validity was observed for
non-Hispanic White, African-American, and Hispanic
persons (57, 58), and modified to include foods typically
eaten by Chinese persons and to collect supplemental infor-
mation concerning hypotheses about whole grains,
processing of plant food, and flavonoids. Questionnaires are
administered at baseline to capture information about anger
and anxiety (the Spielberger trait anger and anxiety scales)
(59), depression (the Center for Epidemiologic Studies
Depression Scale (60)), social support (61), chronic psycho-
logical stress (the chronic burden scale developed for the
Healthy Women Study (62)), perception of discrimination
and unfair treatment (63, 64), and neighborhood environ-
ment, including measures of social cohesion (65) and
selected aspects of the physical environment. Additional
psychosocial domains to be assessed in follow-up visits
include optimism (the Life Orientation Test (66)), hostility
(a subset of the Cook-Medley scale (67)), religiousness/spir-
ituality (68), job stress (69), and quality of life (70).
During the examination, height, weight, and waist and hip
circumferences are measured. Resting blood pressure is
measured three times in the seated position using a Dinamap
model Pro 100 automated oscillometric sphygmomanometer
(Critikon, Tampa, Florida) (71). The average of the last two
measurements will be used in analysis.
Chest computed tomography is performed using either a
cardiac-gated electron-beam computed tomography scanner
(the Chicago, Los Angeles, and New York field centers)
(Imatron C-150; Imatron, San Francisco, California) (72) or
a prospectively electrocardiogram-triggered scan acquisition
at 50 percent of the R-R interval with a multidetector
computed tomography system (73) acquiring a block of four
2.5-mm slices for each cardiac cycle in a sequential or axial
scan mode (the Baltimore, Forsyth County, and St. Paul field
centers) (Lightspeed, General Electric Medical Systems,
Waukesha, Wisconsin; or Volume Zoom, Siemens,
Erlanger, Germany). All participants are scanned over phan-
toms of known physical calcium concentration. Scans are
read centrally at the Harbor-UCLA Research and Education
Institute in Torrance, California, to identify and quantify
coronary calcification, calibrated according to the readings
of the calcium phantom.
Cardiac magnetic resonance imaging is performed using
scanners with 1.5-T magnets. The following models are
being used: Forsyth County—Signa CV/i (General Electric
Medical Systems, Waukesha, Wisconsin); New York—
Signa LX (General Electric); Baltimore—Signa CV/i
(General Electric); St. Paul—Vision and Symphony
(Siemens, Erlanger, Germany); Chicago—Symphony
(Siemens); Los Angeles—Vision (Siemens) and Signa LX
(General Electric). All imaging is performed with a four-
element, phased-array surface coil placed anteriorly and
posteriorly, electrocardiogram gating, and brachial artery
pressure blood pressure monitoring. Imaging consists of cine
images of the left ventricle with time resolution less than 50
msec, as well as phase contrast flow images of the ascending
aorta (74, 75). Images of the carotid arteries (planned for the
second examination) will be obtained with dedicated surface
coils for plaque characterization (76). Readings will be
performed centrally at the Department of Radiology, Johns
Hopkins University School of Medicine.
For carotid ultrasonography, images of the right and left
common carotid and internal carotid arteries are captured,
including images of the near and far wall, using high-resolu-
tion B-mode ultrasound (77). Doppler studies of the
common carotid artery, the internal carotid artery, and the
bulb and distensibility of the distal common carotid artery
are obtained (78, 79). The Logiq 700 ultrasound machine
(General Electric Medical Systems) is used at all centers.
Readings are performed centrally at the Department of Radi-
ology, New England Medical Center.
High-resolution B-mode ultrasound imaging is used to
determine the diameter of the right brachial artery before and
immediately after reactive dilation induced by ischemia (80),
which is produced by inflating a blood pressure cuff to 200
mmHg or to 50 mmHg greater than the systolic blood pres-
sure (whichever is higher) for 5 minutes. Arterial diameter at
baseline and at 60 seconds after cuff deflation are recorded;
the percentage difference is the measure of reactivity. Read-
ings are performed centrally at the Department of Radiology,
New England Medical Center.
Arterial wave forms are recorded using the HDI/Pulse-
Wave CR2000 (Hypertension Diagnostics, Inc., Minneap-
olis, Minnesota) (81). With a tonometer at the radial artery,
10 arterial wave forms will be collected and stored electron-
ically. On the basis of these measures, plus the participant’s
age, sex, height, and weight, measures of small and large
artery compliance are produced by the device using the
manufacturer’s software. Additional readings are performed
centrally at the Department of Radiology, New England
Medical Center.
To obtain the ankle-brachial blood pressure index, blood
pressure is measured with a Doppler probe in the bilateral
brachial, dorsalis pedis, and posterior tibial arteries (82). The
higher of the pressures obtained in the same ankle will be
used as the numerator for the ankle-brachial blood pressure
index for that leg.
For electrocardiography, three 12-lead recordings are
obtained using a Marquette MAC-PC instrument (Marquette
Electronics, Milwaukee, Wisconsin) and read using Nova-
code criteria (83). In addition to standard electrocardiogram-
derived measures, information on R-R variability is
obtained. Readings are performed centrally at Wake Forest
University.
Blood is drawn from participants, and aliquots are
prepared for central analysis and for storage (approximately
65 aliquots per participant) at the University of Vermont and
the University of Minnesota. Measurements will be
performed to allow several domains of study to be addressed,
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hemostasis and fibrinolysis, insulin resistance, oxidative
damage and stress, plaque destabilization, endothelial cell
function, bone metabolism, endocrinology, and nutrition.
DNA is extracted from the buffy coat, and white blood cells
are prepared for cryopreservation and later immortalization
of the lymphocytes. Red blood cell membranes are prepared
and stored for subsequent analysis. A random urine sample is
collected, with one aliquot being analyzed centrally for
albumin and creatinine and the remainder stored.
Notification of and referral for study findings
Study participants and their physicians, as requested by the
participant, receive information on relevant medical tests.
An initial report summarizes results available at the comple-
tion of the first clinic visit, such as height, weight, blood
pressure, and preliminary electrocardiographic findings.
Routine laboratory findings of clinical relevance and results
of computed tomography, magnetic resonance imaging, and
ultrasonography are reported by mail. Any “alert” find-
ings—indications of conditions that should be medically
evaluated on an urgent basis—are reported to the participant
and his or her physician by telephone as soon as they are
identified.
Cohort surveillance and follow-up for events
Study event endpoints will include acute myocardial
infarction and other forms of coronary heart disease, stroke,
peripheral vascular disease, and congestive heart failure;
mortality; and CVD interventions. Silent myocardial infarc-
tions will be identified using criteria applied to the follow-up
electrocardiogram. Resuscitated cardiac arrest and other
CVD endpoints, such as procedure-induced events or pulmo-
nary embolism, will be identified from medical records.
Each participant will be contacted every 9–12 months. Infor-
mation on new CVD conditions, hospitalizations, treat-
ments, and changes in life habits recently instituted will be
obtained. At the first follow-up contact, emphasis will be
placed on obtaining information on diagnostic assessment or
treatment that might have been related to the report of
subclinical disease measured at baseline.
For classification of CVD events occurring during follow-
up in MESA, information will be collected from death certif-
icates, medical records from hospitalizations, autopsy
reports, interviews with participants, and, in the case of out-
of-hospital deaths, interviews with or questionnaires admin-
istered to physicians, relatives, or friends.
Quality assurance and control
Staff are centrally trained and are required to demonstrate
competency in relevant procedures before being certified to
perform those procedures for the MESA examination. This
includes all interviews, phlebotomy and specimen
processing, all blood pressure measurements, anthropom-
etry, electrocardiography, ultrasound procedures, collection
of arterial wave forms, computed tomography, magnetic
resonance imaging, and data entry. Certification is main-
tained by successful performance of the procedure over time,
which is monitored by the MESA Coordinating Center.
Duplicate collections and/or measurements for a
subsample of components, except interviews, will be
obtained to measure reproducibility. The validity of all
measurements will be checked through examination of data
outliers and through external quality control programs (for
example, routine measurement of scans obtained from phan-
toms and performance in independent laboratory quality
maintenance programs).
Data management
Data collected at the field centers are entered onto forms
that are scanned and transmitted to the MESA Coordinating
Center. The scanning software confirms the validity of iden-
tification numbers and the ranges of values and determines
whether appropriate skip patterns were followed. The Coor-
dinating Center uploads the data onto a MESA intranet site
for use by all study centers. Thus, all sites have access to
their own data for read-only (query) purposes. The Coordi-
nating Center creates reports summarizing the status of data
collection. After data collection is complete, including that
for designated interim periods, the data are cleaned and
distributed to investigators.
DISCUSSION
MESA will provide important new information about the
pathophysiology of subclinical disease development and
progression and its role in determining clinical CVD.
Several major dimensions of subclinical CVD, including
cardiac structure and function and conditions of the aorta,
coronary arteries, peripheral arteries, and carotid arteries,
and generalized measures of vascular function and compli-
ance will be explored comprehensively and contemporane-
ously. Assessment of biochemical and genetic factors in
major pathophysiologic domains will complement these
measures. MESA has the potential to identify new risk
factors for CVD and thus increase the ability to predict
CVD and, ultimately, to allow the design of new prevention
strategies. The ethnic diversity of the cohort, albeit limited
to a small number of groups and some relatively small
subgroups, is a unique feature and major strength of the
study, permitting comparisons that may provide unique
insights about interactions between ethnicity, risk factors,
and subclinical and clinical CVD. It is hoped that the
study’s results will be applicable to clinical practice
through the identification of noninvasive subclinical
disease measures that best predict risk and through the
suggestion of new approaches to prevent progression of
subclinical disease.
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Herold, Pamela Schreiner, Eyal Shahar, Charles Dietz, Lori
Boland, Laura Kemmis, Mary Olson, Ana Diaz, Roberto
Galaviz, Jackie Muñoz, Gail Murton, Michelle Neely, Mary
Rosas, Esther Ruiz, Modesto Vasquez, and Pilar Velasquez;
Chicago, Illinois: Northwestern University—Kiang Liu (Prin-
cipal Investigator), Martha Daviglus, Paul Finn, David Green,
Philip Greenland, David McPherson, William Pearce, and
Michelle Woods; University of Illinois—George Kondos;
Loyola University—Richard Cooper; New York, New York:
Columbia University—Steven Shea (Principal Investigator),
Olga Castro, Ana Diez Roux, Marco DiTullio, Geoffrey
Gibson, Shunichi Homma, Carmen Isasi, Ralph Sacco, Rola
Saouaf, and Alan Tall; St. Francis Hospital—Yadon Arad and
Alan Guerci; Baltimore, Maryland: Johns Hopkins Univer-
sity—Moyses Szklo (Principal Investigator), T. J. Blake, Roger
Blumenthal, Carol Christman, Joel Hill, João Lima, Javier
Nieto, Pamela Ouyang, and Wendy Post; Los Angeles, Cali-
fornia: University of California, Los Angeles—Mohammed
Saad (Principal Investigator), Linda Demer, Alan Fogelman,
Jonathan Goldin, Antoinette Gomes, Edward Grant, Rebecca
Hua, Willa Hsueh, Sujata Jinagouda, Michael McNitt-Gray,
Ying Mou, Shantanu Sinha, and Nancy Zambrana; Central
Laboratory—University of Vermont: Russell P. Tracy (Prin-
cipal Investigator), Elaine Cornell, Mary Cushman, and Nancy
Jenny; University of Minnesota: Naomi Hanson and Michael
Tsai; Electrocardiogram Reading Center—Ronald Prineas
(Principal Investigator) and Farida Rautaharju; Ultrasound
Reading Center—New England Medical Center: Daniel
O’Leary (Principal Investigator), Laurie Funk, and Joseph
Polak; MRI Reading Center—Department of Radiology, Johns
Hopkins University: David Bluemke (Principal Investigator),
João Lima, and Linda Wilkins; CT Reading Center—Harbor-
UCLA Research and Education Institute: Robert Detrano (Prin-
cipal Investigator), Matthew Budoff, Chris Dailing, Hans
Fischer, Jeffrey Phillips, Susan Rice, and Nan Zhuang; Univer-
sity of California at Irvine: Nathan Wong; University of Cali-
fornia at San Diego: Michael Criqui; Coordinating Center—
University of Washington: Richard Kronmal (Principal Investi-
gator), Melissa Anderson, Norma Dermond, Annette Fitz-
patrick, Susan Heckbert, Bonnie Lind, Will Longstreth, Jennifer
Clark Nelson, Bruce Psaty, David Siscovick, and Patricia Wahl;
Project Office—National Heart, Lung, and Blood Institute:
Diane Bild (Project Officer), Andrew Arai, Robin Boineau, Teri
Manolio, Jean Olson, and A. Richey Sharrett.
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APPENDIX
Major Subclinical Cardiovascular Disease Variables on 
which Data are Available for Analysis, Multi-Ethnic Study 
of Atherosclerosis, 2000–2007
Cardiac computed tomography
Agatston score, volume, volumetric score, and mass for the
four major coronary arteries and for the sum of all arteries
Carotid ultrasound
Intimal-medial thickness measurements of left and right
common and internal carotid arteries
Lumen measurements for both left and right carotid
arteries
Normal lumen diameter for common and internal carotid
artery
Minimum residual lumen diameter for common and
internal carotid artery






Doppler velocity at point of maximum disease
Distensibility of the common carotid artery
Endothelial function
Percent reactivity
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Cardiac output
End diastolic wall thickness
End systolic wall thickness
Thoracic aorta distensibility
Thoracic aorta cross-sectional area
Carotid magnetic resonance imaging
Plaque characterization
Ankle-brachial index
Electrocardiography and rhythm strip
Major and minor electrocardiogram abnormalities
R-R variability
Arterial wave form
Large artery elasticity index
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